Price controls in any industry do not work and inevitably lead to shortages and disrupted markets. Price controls on biopharmaceuticals are especially harmful because they raise costs, stifle research and development of new cures and treatments, and threaten America’s position as the global industry leader. As the Inflation Reduction Act (IRA) was being considered by […]
Welcome to This Week in Waste, a series by Citizens Against Government Waste (CAGW) that highlights how taxpayer dollars are being wasted in the federal, state, and local levels of government and efforts to fight back against this spendthrift behavior. Senate Health, Education, Labor, and Pensions (HELP) Committee Hearing is Next Step for 340B Reform The […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
Improper payments have long been an avoidable drain on the federal budget and are often prominently featured as an example of wasteful spending. It is therefore not surprising that in the August 12, 2025, Government Accountability Office (GAO) updated report on open recommendations to improve government operations, reducing fraud and improper payments was first on […]
Prices controls have always disrupted the marketplace and created shortages or excesses.
The Inflation Reduction Act creates instability in the Medicare Part D Program.
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
Taxpayers and beneficiaries should be concerned with the Biden administration’s proposed cuts to Medicare Advantage.
IRA drug price controls will devastate future drug development, resulting in more lives lost.
House Democrats’ new bill on price controls will devastate future drug development and raise costs.
